BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22971456)

  • 1. Serum albumin levels in women with ovarian hyperstimulation syndrome with or without polycystic ovaries.
    Alserri A; Holzer H; Tulandi T
    J Obstet Gynaecol Can; 2012 Sep; 34(9):866-869. PubMed ID: 22971456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries.
    Agrawal R; Conway G; Sladkevicius P; Tan SL; Engmann L; Payne N; Bekir J; Campbell S; Jacobs H
    Fertil Steril; 1998 Oct; 70(4):651-8. PubMed ID: 9797093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A relation between the polycystic ovary syndrome and the status of ovarian hyperstimulation syndrome in IVF patients after controlled hyperstimulation].
    Moosová M; Moos J; Filová V; Pavelková J; Jarosová R; Rezábek K
    Ceska Gynekol; 2011 Apr; 76(2):123-7. PubMed ID: 21649996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the clinical outcomes of IVF-ET treatment in infertile patients with polycystic ovary syndrome or polycystic ovaries].
    Wang QL; Song J; Chen SL; Luo C; Chen X; Li M; Ni YP
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):962-5. PubMed ID: 19460721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IVF outcome in women with PCOS, PCO and normal ovarian morphology.
    Swanton A; Story L; McVeigh E; Child T
    Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):68-71. PubMed ID: 20022685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe ovarian hyperstimulation syndrome (OHSS) and icterus.
    Nawroth F; Heinrich J; Bruns U; Wood WG
    Hum Reprod; 1996 Nov; 11(11):2441-2. PubMed ID: 8981129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.
    Enskog A; Henriksson M; Unander M; Nilsson L; Brännström M
    Fertil Steril; 1999 May; 71(5):808-14. PubMed ID: 10231037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent megalocystic ovary following in vitro fertilization in a postpartum patient with polycystic ovarian syndrome.
    Ling SY; Chong KM; Hwang JL
    Taiwan J Obstet Gynecol; 2006 Mar; 45(1):70-2. PubMed ID: 17272214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization.
    Zhu WJ; Li XM; Chen XM; Zhang L
    Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):79-84. PubMed ID: 16154042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the oral contraceptive pill on patients undergoing controlled ovarian hyperstimulation.
    Frederick J; DaCosta V; Wynter S; Reid M; Frederick C; McKenzie C
    West Indian Med J; 2004 Jan; 53(1):39-43. PubMed ID: 15114893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of polycystic ovary syndrome with onset of severe ovarian hyperstimulation syndrome following controlled ovarian stimulation with aromatase inhibitors for fertility preservation before breast cancer treatment.
    Oishi S; Mekaru K; Nakamura R; Miyagi M; Akamine K; Heshiki C; Aoki Y
    Taiwan J Obstet Gynecol; 2021 Sep; 60(5):931-934. PubMed ID: 34507678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total ovarian volume before human chorionic gonadotrophin administration for ovulation induction may predict the hyperstimulation syndrome.
    Oyesanya OA; Parsons JH; Collins WP; Campbell S
    Hum Reprod; 1995 Dec; 10(12):3211-12. PubMed ID: 8822446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome].
    Zhu RR; Xiao SQ; Zhao JZ; Lin J; Wang PY; Jin CC; Jin WM
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):833-7. PubMed ID: 24444560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of serum miRNAs in the prediction of ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients.
    Zhao C; Liu X; Shi Z; Zhang J; Zhang J; Jia X; Ling X
    Cell Physiol Biochem; 2015; 35(3):1086-94. PubMed ID: 25662703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization.
    MacDougall MJ; Tan SL; Balen A; Jacobs HS
    Hum Reprod; 1993 Feb; 8(2):233-7. PubMed ID: 8473426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.